Overview

A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-10-28

Target enrollment:

Participant gender:

Summary

For patients with early- to mid-stage hepatocellular carcinoma (HCC), the five-year postoperative recurrence and metastasis rate remains as high as 70%, significantly impacting patient prognosis.Therefore, perioperative therapy may be considered for HCC patients with these high-risk features .

Phase:

Details

Lead Sponsor:

Tongji Hospital